✦ LIBER ✦

OP-007 Evaluation Of Effectiveness And Safety Of Everolimus Eluting Stent System (XIENCE V) In Acute Coronary Syndrome Patients

✍ Scribed by Karakulak, U.N.; Yorgun, H.; Şahiner, L.; Kaya, B.; Kabakçı, G.; Aytemir, K.; Oto, A.

Book ID: 122250219
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 46 KB
Volume: 113
Category: Article
ISSN: 0002-9149
DOI: 10.1016/j.amjcard.2014.01.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

OP-008 Evaluation of Effectiveness and S

OP-008 Evaluation of Effectiveness and Safety of Everolimus Eluting Stent System (XIENCE V) in Patients with Atrial Fibrillation

✍ Karakulak, U.N.; Yorgun, H.; Şahiner, L.; Kaya, B.; Kabakçı, G.; Aytemir, K.; Ot 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 46 KB

OP-069 Evaluation of Effectiveness and S

OP-069 Evaluation of Effectiveness and Safety of Everolimus Eluting Stent System (XIENCE V) in the Treatment of Coronary Artery Lesions

✍ Karakulak, U.N.; Yorgun, H.; Şahiner, L.; Kaya, B.; Kabakçı, G.; Aytemir, K.; Ot 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 186 KB

TCT-45 Long Term Safety and Effectivenes

TCT-45 Long Term Safety and Effectiveness of XIENCE V® Everolimus Eluting Coronary Stent System in Real-World Population: Three-Year Clinical Outcomes from the XIENCE V® USA Study

✍ James Hermiller Jr; Mitchell Krucoff; weiying zhao; Luis Gruberg; William Lombar 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Outcomes in Diabetic and Nondiabetic Pat

Outcomes in Diabetic and Nondiabetic Patients Treated With Everolimus- or Paclitaxel-Eluting Stents: Results From the SPIRIT IV Clinical Trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System)

✍ Dean J. Kereiakes; Donald E. Cutlip; Robert J. Applegate; John Wang; Manejeh Yaq 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 349 KB

Comparison of Everolimus-Eluting and Pac

Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention: The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials

✍ Dean J. Kereiakes; Krishnankutty Sudhir; James B. Hermiller; Paul C. Gordon; Joa 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 939 KB

Pharmacokinetic Sub-Study in the SPIRIT

Pharmacokinetic Sub-Study in the SPIRIT III Randomized and Controlled Trial of XIENCE V® Everolimus Eluting Coronary Stent System

✍ QING WANG; WESLEY PIERSON; POORNIMA SOOD; CORNELIS BOL; LOUIS CANNON; PAUL GORDO 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB